AHA shares proposals to lower Medicare drug prices with Congress
In a statement submitted to the Senate Finance Committee for a hearing yesterday on lowering drug prices in Medicare, AHA encouraged Congress to implement policies that would increase generic alternatives and discourage anti-competitive tactics while maintaining incentives to develop innovative new therapies. AHA also called for policies to increase transparency in drug pricing; provide rebates to Medicare when a drug’s average manufacturer or sales price exceeds inflation; better align incentives in the Part D reinsurance program; and protect the 340B Drug Pricing Program.
Related News Articles
Perspective
Hospitals and health systems — and the women and men who work there — are the heart of health care. In good times like the birth of a child, or in bad…
Headline
The Centers for Medicare & Medicaid Aug. 15 announced it negotiated lower prices with drug makers for 10 high-cost, sole-source drugs, with the new prices…
Headline
The Senate Appropriations Committee Aug. 1 voted 25-3 to approve legislation that would provide $231.3 billion in funding for the departments of Labor, Health…
Headline
During the July 22 morning plenary session, Stacey Hughes, AHA’s executive vice president of government relations and public policy, moderated a panel with…
Headline
The Centers for Medicare & Medicaid Services July 16 released its final guidance on the Medicare Prescription Payment Plan which will begin next year. The…
Headline
The AHA July 15 commented to Sens. Sheldon Whitehouse, D-R.I., and Bill Cassidy, R-La., responding to a request for information based on the Pay PCPs Act,…